JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib. - Ceccardi A; Dameri M; Ravera F; Gilardi N; Stabile M; Lombardo I; Ceresa D; Colombo M; Vigo T; Cigolini B; Rivoli G; Dragani M; et al. (British journal of haematology, 2025)